Table 1.

Disposition of subjects during the extension study

Original cinacalcet a (n = 334)Original placebo (n = 255)
Enrolled in extension study, n334255
Did not receive study medication, n (%)1 (<1)3 (1)
Received study medication, n (%)333 (100)252 (99)
Titration phase—weeks 1–8, n (%)
    Started333 (100)252 (99)
    Discontinued15 (4)18 (7)
    Completed318 (95)234 (92)
Maintenance phase—weeks 9–32, n (%)
    Started318 (95)234 (92)
    Discontinued56 (17)50 (20)
    Completed262 (78)184 (72)
Follow-up phase—weeks 33–164, n (%)
    Started b261 (78)182 (71)
    Discontinued136 (41)103 (40)
    Completed125 (37)79 (31)
Total discontinued209 (63)176 (69)
Subjects rolled over to extension study, n (%)
    After 6 mo c236 (71)150 (59)
    After 12 mo d98 (29)105 (41)
  • a All subjects who had 26 to 52 wk of cinacalcet therapy prior to study entry.

  • b One original cinacalcet and two original placebo subjects completed maintenance phase and did not start follow-up phase.

  • c Subjects completing studies A, B, and C.

  • d Subjects completing studies D and E.